Search Results
Sort by:
Filter 0
Sort by
21 April 2018 - P0274
Efficacy of oral omadacycline versus linezolid for treating adult subjects with ABSSSI: analysis by infection type and pathogen in the OASIS-2 study
21 April 2018 - P0275
Omadacycline versus moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia (CABP): efficacy analysis according to EMA requirements
21 April 2018 - P0288
Real-life experience with ceftolozane-tazobactam in haematological patients with Pseudomonas infection: a case-control study
21 April 2018 - P0283
Potential cost savings opportunities with targeted iclaprim (ICL) compared to vancomycin (VAN) among hospitalized patients with acute bacterial skin and skin structure infectious due to potential avoidance of VAN-associated acute kidney injury
21 April 2018 - P0282
Reduced hospital stays for skin infections treated with dalbavancin
21 April 2018 - P0279
Clinical experience with telavancin for the treatment of obese patients (BMI >30 kg/m2): preliminary results from the Telavancin Observational Use Registry (TOUR)
21 April 2018 - P0281
Staphylococcal-selective antibiotic afabicin preserves the human gut microbiota
21 April 2018 - P0271
Omadacycline gastrointestinal effects — an integrated safety analysis from the phase-3 ABSSSI and CABP studies
21 April 2018 - P0272
Efficacy of omadacycline versus moxifloxacin in treating subjects from different geographic regions with community-acquired bacterial pneumonia (CABP)
21 April 2018 - P0284
Plazomicin is associated with fewer post-baseline infectious complications compared with colistin in patients with serious infections due to carbapenem-resistant Enterobacteriaceae (CRE): results from the randomized, controlled CARE study
21 April 2018 - P0273
Effects of oral omadacycline versus oral linezolid on lesion size and local signs of ABSSSI in the phase-3 OASIS-2 study
21 April 2018 - P0290
Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa (MDRPA) infections: a multicentre study
21 April 2018 - P0280
Clinical experience with telavancin for the treatment of elderly patients (>=65 years): preliminary results from the telavancin observational use registry (TOUR)
21 April 2018 - P0286
Multicentre evaluation of ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections
21 April 2018 - P0285
Meropenem-vaborbactam versus best-available therapy for carbapenem-resistant Enterobacteriaceae infections in TANGO II: outcomes in patients with cancer
21 April 2018 - P0277
Lefamulin is non-inferior to moxifloxacin in adults with community-acquired bacterial pneumonia (CABP): the phase 3 lefamulin evaluation against pneumonia (LEAP 1) study
21 April 2018 - P0278
Alternatives to the all-cause mortality (ACM) endpoint for studies of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP)
21 April 2018 - P0287
Ceftolozane-tazobactam for the treatment of Pseudomonas aeruginosa infection in a tertiary hospital: clinical outcome and develop of resistance
21 April 2018 - P0289
Efficacy and safety of ceftolozane/tazobactam as salvage therapy in severely ill patients
21 April 2018 - P0276
Lefamulin demonstrates favorable safety and tolerability in adults with community-acquired bacterial pneumonia (CABP) in the phase-3 lefamulin evaluation against pneumonia (LEAP 1) study
Loading ...
FAQ
To access content in the eLibrary you need to log in with your ESCMID member or user credentials. If you haven’t registered as an ESCMID member yet, then click here to do so – or use this link to register as a user.
The most recent event-related content is usually restricted to ESCMID members, while registered users get access one year after the event. However, there are events such as ECCMID where attendees get priority access, no matter if they are members or registered users. In these cases, we may offer non-attendees access after paying a fee.
You may search by event name, session title or number, topic title or number or author – or by any keyword. To get the most relevant results, enter the title or name in quotation marks, e.g. "Pre-ECCMID Day on Diagnostics" or "John Doe". If no quotation marks are used, then the exact result is shown first, followed by less exact results.
You may further narrow the number of search results for most terms by applying one or several filters, using the filter window on the start page. The Category and Media Type filters work for any content. In contrast, the Date from / to filter may not apply for Publications and Guidelines. In addition, the information text below a webcast or document offers the option of filtering search results by session title, author, event or category.
We defined four "hot topic" terms that you may search for by clicking the four tiles on the start page.
Linking two or more search terms by AND will show all results containing these search terms. For example, if you are looking for results that contain both the terms viral and hospital, then enter viral AND hospital.
Link two or more search terms by OR to get all results that contain at least one of these terms. For example, if you want to get results that contain either viral or infections or COVID, then enter viral OR infections OR COVID.
Place + in front of the term that you want to be included in your search result and place - in front of the term that you do not want to be included – without blanks in between in either case. For example, if you are aiming for search results that contain viral and infection but do not contain COVID, then enter +viral +infections -COVID.
A search term preceded by an exclamation point (no blanks in between) will lead to all content that does not contain the term, e.g. !COVID.
Deselect the ticked boxes in the filter dropdowns, click "Clear" on the calendars in the Date from / to filter – or refresh the website to remove all filters at once. Additionally, you may clear all applied filters by using the relevant buttons right above the search results.
No, as copyright protection limits the viewing of video presentations to web browsers, they cannot be downloaded.
No, due to our privacy policy we cannot disclose any contact details of persons involved.